These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34920368)

  • 1. BRCA1/2 testing for genetic susceptibility to cancer after 25 years: A scoping review and a primer on ethical implications.
    Petrova D; Cruz M; Sánchez MJ
    Breast; 2022 Feb; 61():66-76. PubMed ID: 34920368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of decision aids for female BRCA1 and BRCA2 mutation carriers in Germany to support preference-sensitive decision-making.
    Kautz-Freimuth S; Redaèlli M; Rhiem K; Vodermaier A; Krassuski L; Nicolai K; Schnepper M; Kuboth V; Dick J; Vennedey V; Wiedemann R; Schmutzler R; Stock S
    BMC Med Inform Decis Mak; 2021 Jun; 21(1):180. PubMed ID: 34090422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?
    Vos S; van Diest PJ; Moelans CB
    Crit Rev Oncol Hematol; 2018 Jul; 127():29-41. PubMed ID: 29891109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicolegal and insurance issues regarding
    Oliva R; Grassi S; Marchetti C; Cazzato F; Marinelli R; Scambia G; Fagotti A
    Int J Gynecol Cancer; 2024 Jun; 34(6):935-941. PubMed ID: 38642925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of Variants.
    Machackova E; Claes K; Mikova M; Házová J; Sťahlová EH; Vasickova P; Trbusek M; Navrátilová M; Svoboda M; Foretová L
    Klin Onkol; 2019; 32(Supplementum2):51-71. PubMed ID: 31409081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decision aids for female BRCA mutation carriers: a scoping review.
    McGarrigle SA; Prizeman G; Spillane C; Byrne N; Drury A; Polus M; Mockler D; Connolly EM; Brady AM; Hanhauser YP
    BMJ Open; 2024 Jun; 14(6):e076876. PubMed ID: 38871662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
    Riedlova P; Janoutova J; Hermanova B
    Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
    Shimada S; Yoshida R; Nakashima E; Kitagawa D; Gomi N; Horii R; Takeuchi S; Ashihara Y; Kita M; Akiyama F; Ohno S; Saito M; Arai M
    Breast Cancer; 2019 Nov; 26(6):846-851. PubMed ID: 30980249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.
    Villarreal-Garza C; Alvarez-Gómez RM; Pérez-Plasencia C; Herrera LA; Herzog J; Castillo D; Mohar A; Castro C; Gallardo LN; Gallardo D; Santibáñez M; Blazer KR; Weitzel JN
    Cancer; 2015 Feb; 121(3):372-8. PubMed ID: 25236687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2.
    Ingham SL; Warwick J; Buchan I; Sahin S; O'Hara C; Moran A; Howell A; Evans DG
    J Med Genet; 2013 Jun; 50(6):368-72. PubMed ID: 23539753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Building the What Comes Next Cohort for
    Dossa F; Metcalfe K; Sutradhar R; Little T; Eisen A; Chun K; Meschino WS; Velsher L; Ellis JL; Baxter NN
    CMAJ Open; 2021; 9(3):E874-E885. PubMed ID: 34870614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer.
    Nilsson MP; Winter C; Kristoffersson U; Rehn M; Larsson C; Saal LH; Loman N
    Fam Cancer; 2017 Apr; 16(2):187-193. PubMed ID: 28120249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventive surgery is associated with reduced cancer risk and mortality in women with BRCA1 and BRCA2 mutations.
    Domchek SM; Rebbeck TR
    LDI Issue Brief; 2010; 16(2):1-4. PubMed ID: 21545057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations.
    Solsky I; Chen J; Rebbeck TR
    Gynecol Oncol; 2020 Feb; 156(2):363-376. PubMed ID: 31918993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Family planning in carriers of BRCA1 and BRCA2 pathogenic variants.
    Haddad JM; Robison K; Beffa L; Laprise J; ScaliaWilbur J; Raker CA; Clark MA; Hofstatter E; Dalela D; Brown A; Bradford L; Toland M; Stuckey A
    J Genet Couns; 2021 Dec; 30(6):1570-1581. PubMed ID: 33904624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
    Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
    Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing.
    Riahi A; Chabouni-Bouhamed H; Kharrat M
    Cancer Genet; 2017 Jan; 210():22-27. PubMed ID: 28212807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Nelson HD; Pappas M; Cantor A; Haney E; Holmes R
    JAMA; 2019 Aug; 322(7):666-685. PubMed ID: 31429902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
    Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
    Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.